Drug Profile
Research programme: protein complexes - Redbiotec/Roche
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Roche
- Developer Redbiotec; Roche
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Switzerland
- 02 Dec 2010 Early research in Undefined indication in Switzerland (unspecified route)